Abstract: |
The liver is the most common site of metastatic disease in patients with colorectal cancer (CRC). However, only 5%-10% of patients with CRC have metastatic lesions that are amenable to curative resection. Current management of patients with potentially downstageable unresectable CRC metastases involves an aggressive multimodality approach led by an interdisciplinary team of surgeons, medical oncologists, pathologists, and diagnostic radiologists. Efforts to increase the proportion of patients eligible for curative resection have led to improvements in prognostic factors for patient selection, advancements in surgical techniques, and implementation of multimodality approaches involving neoadjuvant chemotherapy, hepatic arterial infusion, preoperative portal vein embolization, local ablative therapy through radiofrequency ablation or cryosurgery, and staged resection. This article focuses on the use of neoadjuvant chemotherapy for hepatic CRC metastasis and patient selection criteria for resection of these metastases. © 2006 Elsevier Inc. All rights reserved. |